AI in Precision Medicine Market

Overview

The global AI in Precision Medicine Market was valued at USD 3.1 billion in 2025 and is projected to reach USD 24.8 billion by 2034, growing at a CAGR of 26% during the forecast period (2026–2034). The growth in the market is driven by the rapid expansion of genomic and multiomic testing, rising volumes of clinical and imaging data, and the need to match each patient with the right therapy faster. Drug developers are also using AI to select trial participants, identify biomarkers, and reduce late-stage failures, which is widening commercial demand beyond clinical laboratories. The market is shifting from conventional, standalone algorithms that read a single data type toward multimodal platforms that combine sequencing results, pathology slides, radiology images, and electronic health records in one workflow. Vendors are moving from research-use software to regulated, clinically validated tools, with companion diagnostic claims and cleared digital pathology systems becoming a point of differentiation. Government initiatives such as the European Health Data Space Regulation, which entered into force on 26 March 2025, are creating a legal basis for the secondary use of health data in research and innovation, including the development of AI. The framework sets up national health data access bodies and a cross-border infrastructure for permitted data reuse, with core secondary-use provisions scheduled to apply from March 2029. Clearer data access rules are expected to give European developers broader and better governed datasets for training and validating precision medicine models. By Region, North America held the largest share of the market in 2025, supported by a dense base of precision oncology companies, large clinical genomic datasets, and early adoption of AI-enabled diagnostics across academic cancer centers in the United States. Asia-Pacific is expected to be the fastest-growing region during the forecast period, as hospitals and drug developers in China, India, Japan, and South Korea expand genomic testing and digital pathology programs.

Market Size & Share

Market Dynamics

KEY MARKET TREND

Multimodal Foundation Models and Agentic AI Emerging as a Transformational Trend

• Developers are training foundation models on combined genomic, pathology, imaging, and clinical record data instead of building a separate model for each data type. These models can be adapted to new cancer types and biomarker questions with limited extra labeling. This shortens the path from a research idea to a usable decision-support tool for clinicians and drug developers.
• Agentic AI assistants are entering research and clinical workflows to read literature, query patient cohorts, and draft evidence summaries. Biopharma teams use them to screen targets and plan trials, while hospitals test them for tumor board preparation. Vendors now compete on how clearly these tools show their reasoning, because scientists and regulators expect traceable outputs.
• Pharmaceutical companies increasingly license patient data and AI models together, which ties model quality to the depth of a vendor's curated dataset. This favors companies with large clinico-genomic collections and pushes smaller developers toward partnerships with hospitals, laboratories, and data networks. The result is a market where data access shapes competitive position as much as algorithm design.
• Tempus AI announced multi-year strategic agreements with AstraZeneca and Pathos AI to build a multimodal foundation model in oncology. The model is intended to generate biological and clinical insights, discover drug targets, and support therapeutic development for the broader oncology community. The deal shows how data owners, drug developers, and AI specialists are pooling assets.

KEY MARKET DRIVER

Rising Volume of Genomic and Multiomic Patient Data is the Key Driver of AI Adoption

• Falling sequencing costs have moved whole exome, whole transcriptome, and liquid biopsy testing into routine cancer care, producing far more data per patient than laboratory staff can interpret manually. AI-based variant classification and prioritization cuts review time per case. This workload pressure is a direct reason hospitals and reference laboratories are adopting interpretation software.
• Biopharmaceutical companies need reliable biomarkers to select patients for targeted therapies and immunotherapies, and late-stage trial failures remain costly. AI-driven patient stratification helps sponsors identify likely responders earlier and design smaller, better-targeted studies. This creates recurring demand for software, data licensing, and analytics services across oncology and a widening set of disease areas.
• Oncologists must apply growing guideline libraries and an expanding list of approved targeted drugs at the point of care. Clinical decision support tools that match a tumor profile with suitable therapies and eligible trials save physician time. Adoption rises as hospitals connect these tools to electronic health records and molecular tumor boards.
• Illumina and NVIDIA announced a collaboration to run Illumina's DRAGEN genomic analysis algorithms on NVIDIA GPUs and to develop biological foundation models. The work also plans to add NVIDIA image processing and single-cell analysis tools to Illumina Connected Software, aiming to speed multiomic analysis for drug developers and clinical researchers.

KEY MARKET OPPORTUNITY

Expansion of AI-Enabled Companion Diagnostics and Decentralized Testing Creating New Revenue Streams

• Companion diagnostics that pair a validated assay with AI-based interpretation open a recurring revenue path, because each approved targeted therapy needs a matching test. Drug developers now seek diagnostic partners earlier in development, often before pivotal trials begin. Vendors with regulatory experience and clinical-grade assays are well placed to win long-term biopharma contracts.
• Cloud-delivered software lets community hospitals and regional laboratories run advanced genomic analysis in-house without building large bioinformatics teams. This brings precision medicine tools to centers that currently send samples to large reference laboratories in other cities. Subscription and per-analysis pricing give vendors predictable revenue and a growing installed base across regions.
• Disease areas beyond oncology remain largely untapped. Neurology, cardiology, immunology, and rare disease programs are building genomic and imaging datasets that can support AI-based risk prediction, patient grouping, and treatment matching. Early commercial offerings in these areas face fewer competitors than oncology, which is attracting venture and corporate investment into specialized startups.
• Caris Life Sciences received FDA approval for MI Cancer Seek as a companion diagnostic. The company describes it as the first test combining whole exome and whole transcriptome sequencing with approved companion diagnostic claims for solid tumors, for adults and pediatric patients aged 1 to 22. The approval shows a clear regulatory route for comprehensive molecular profiling.

AI in Precision Medicine Market Size, 2025-2034 (USD Billion)

Segmentation Analysis

Analysis by Component

Software held the largest market share in 2025 because laboratories, hospitals, and drug developers need platforms that convert raw sequencing, imaging, and clinical records into decisions. Variant interpretation tools, cloud analytics platforms, and clinical decision support applications are licensed on recurring subscriptions, which gives vendors stable revenue and high customer retention. Regulatory milestones such as CE-IVD marking and FDA clearance of AI-enabled software have also made buyers more comfortable moving these tools from research into routine clinical use. Integration with laboratory information systems and electronic health records raises switching costs and keeps software at the center of most purchasing decisions.

Services are projected to grow at the fastest CAGR during the forecast period as biopharmaceutical companies and health systems outsource data curation, biomarker analysis, model development, and clinical interpretation to specialist providers. Many buyers lack in-house bioinformatics and data science teams, so they prefer managed analysis, custom algorithm development, and real-world data access under multi-year agreements. Growing use of AI-enabled central laboratory and companion diagnostic development services in clinical trials adds further demand. As generative and agentic AI tools are deployed, implementation, validation, and workflow support services are expected to expand alongside the software they support.

Component categories include

• Software (Dominating Segment)
• Services (Highest CAGR Segment)
• Hardware

Analysis by Technology

Machine Learning held the largest market share in 2025 because it is the most established and widely validated technique for tasks such as variant pathogenicity prediction, patient stratification, survival modeling, and treatment response prediction. It performs well on structured genomic, laboratory, and clinical data, needs less computing capacity than newer model types, and is easier to explain to clinicians and regulators. Most commercial products on the market, from laboratory interpretation software to trial matching tools, still rely on supervised and ensemble methods, which keeps this technology at the base of vendor portfolios and procurement decisions.

Deep Learning is projected to grow at the fastest CAGR during the forecast period, supported by its ability to learn directly from complex data such as whole slide pathology images, radiology scans, and raw genomic sequences. Advances in GPU computing and the arrival of large biological foundation models are widening the range of problems it can address, including biomarker discovery from routine stained slides and prediction of treatment response from multimodal records. Growing regulatory acceptance of cleared AI imaging and pathology software, together with pharmaceutical investment in image-based biomarkers, is expected to accelerate adoption.

Technology categories include

• Machine Learning (Dominating Segment)
• Deep Learning (Highest CAGR Segment)
• Natural Language Processing
• Computer Vision
• Context-Aware Computing

Analysis by Application

Diagnostics held the largest market share in 2025 because molecular profiling, digital pathology, and variant interpretation already generate paid, reimbursed testing volumes in oncology and rare disease. Laboratories use AI to classify variants, predict tissue of origin, and read pathology slides, which shortens turnaround times and reduces manual review. The availability of companion diagnostic approvals and clinical guidelines that recommend broad molecular testing has made diagnostic use the most commercially mature application. Recurring test orders from oncologists and genetic specialists give this application a more predictable demand base than research-stage uses.

Drug Discovery is projected to grow at the fastest CAGR during the forecast period as pharmaceutical companies invest in AI to identify targets, select biomarkers, and understand disease biology using large patient and cell-level datasets. Partnerships between data owners, AI developers, and large drug makers are expanding, with multi-year agreements for shared models and licensed datasets becoming more common. The goal is to raise clinical success rates and reduce the time taken to reach the clinic. As genomic perturbation datasets and biological foundation models mature, precision medicine teams are expected to use them earlier in target validation.

Application categories include

• Diagnostics (Dominating Segment)
• Drug Discovery (Highest CAGR Segment)
• Treatment Selection
• Clinical Trial Design
• Others

Analysis by Therapeutic Area

Oncology held the largest market share in 2025 because cancer care has the most advanced biomarker-driven treatment landscape, with many approved targeted therapies and immunotherapies that depend on molecular testing. Tumor profiling, digital pathology, and treatment matching tools are routinely used by cancer centers, and drug developers run a large share of precision trials in this area. Large clinico-genomic datasets built by oncology-focused companies provide training material that other disease areas still lack. Clinical guidelines that recommend comprehensive genomic profiling for advanced cancers sustain steady test volumes and software demand.

Neurology is projected to grow at the fastest CAGR during the forecast period as researchers apply AI to brain imaging, genetic risk markers, and longitudinal patient records to understand complex conditions such as Alzheimer's disease, Parkinson's disease, and epilepsy. Approval of disease-modifying therapies for neurodegenerative conditions has increased the need to identify suitable patients earlier, which supports demand for biomarker and risk prediction tools. Large brain imaging and genomic cohorts are becoming available to developers, and drug makers are widening neurology pipelines, which together create a larger addressable base from a smaller starting point than oncology.

Therapeutic Area categories include

• Oncology (Dominating Segment)
• Neurology (Highest CAGR Segment)
• Cardiology
• Immunology
• Infectious Diseases
• Others

Analysis by End User

Biopharmaceutical Companies held the largest market share in 2025 because they are the heaviest buyers of AI-enabled biomarker analysis, patient data licensing, and trial design services. Drug developers face high clinical failure costs and use precision medicine tools to select patients, support companion diagnostic programs, and generate evidence for regulators. Large pharmaceutical groups sign multi-year agreements with data and AI vendors, which produce sizeable contract values compared with single hospital purchases. Their consistent research spending across oncology, neurology, and immunology keeps this group at the top of the end user mix.

Healthcare Providers is projected to grow at the fastest CAGR during the forecast period as hospitals and cancer centers move AI tools from research projects into routine care. In-house genomic testing, digital pathology, and clinical decision support are being adopted to improve treatment matching and shorten time to results. Cloud-based delivery lets health systems start without building large bioinformatics teams. Growing links between molecular tumor boards, electronic health records, and AI software support wider use, while reimbursement for comprehensive genomic testing in more markets improves the business case for provider-led programs.

End User categories include

• Biopharmaceutical Companies (Dominating Segment)
• Healthcare Providers (Highest CAGR Segment)
• Diagnostic Laboratories
• Academic Research Institutes
• Others

By Region

North America held the largest market share in 2025, accounting for 46% of global revenue. The United States leads through a concentrated base of precision oncology companies, large clinical genomic datasets, and academic cancer centers that adopt AI tools early. The US Food and Drug Administration clears AI-enabled software and approves companion diagnostics, which gives vendors a defined regulatory route, while the National Institutes of Health runs the All of Us Research Program to build a diverse national research dataset. Canada contributes through publicly funded genomics research and growing hospital adoption of molecular profiling, while Mexico remains at an earlier stage. The competitive landscape includes Tempus AI, Illumina, Caris Life Sciences, NVIDIA, and PathAI, all headquartered in the region.

Asia-Pacific is projected to grow at the fastest CAGR during the forecast period, rising from about 21% of global revenue in 2025 to about 30% by 2034. China, India, Japan, and South Korea are the main contributors. Government-backed genomic programs, including India's GenomeIndia project and South Korea's national bio big data initiatives, are expanding population-scale datasets that AI developers can use. Hospitals are installing digital pathology and tumor profiling systems, and South Korean developers such as Lunit supply AI biomarker software to global drug developers. Regulators in the region are building review pathways for software as a medical device, which supports commercial launches. Competition is rising as international vendors partner with local hospitals while regional companies scale.

Countries and Regions Covered

North America (Dominating Region)

• United States (Largest Country Market)
• Canada
• Mexico

Asia-Pacific (Fastest Growing Region)

• China (Largest Country Market)
• India (Fastest-Growing Country Market)
• Japan
• South Korea
• Rest of Asia-Pacific

Europe

• Germany (Largest Country Market)
• France
• United Kingdom
• Italy
• Rest of Europe

Latin America

• Brazil (Largest Country Market)
• Chile (Fastest-Growing Country Market)
• Rest of Latin America

Middle East & Africa

• Saudi Arabia (Largest Country Market)
• United Arab Emirates (Fastest-Growing Country Market)
• Rest of Middle East & Africa

Market Share

The AI in Precision Medicine Market is fragmented, with a small group of data-rich platform leaders sitting alongside many specialist software and service providers. Companies such as Tempus AI, Illumina, Caris Life Sciences, NVIDIA, and Roche hold strong positions through large patient datasets, sequencing and computing platforms, or regulated diagnostic portfolios. Key success factors include access to curated clinico-genomic data, regulatory clearances, hospital and biopharma relationships, and cloud scalability. Leading companies are prioritizing multimodal platforms, companion diagnostic development, and agentic AI tools for researchers. Innovation is focused on foundation models, digital pathology biomarkers, and explainable variant interpretation. Partnership and acquisition activity is steady, as data owners, drug developers, and AI specialists combine assets to broaden datasets and speed commercialization.

Key Players

• Tempus AI, Inc. (US)
• Illumina, Inc. (US)
• NVIDIA Corporation (US)
• Caris Life Sciences, Inc. (US)
• Roche Holding AG (Switzerland)
• Owkin (France)
• SOPHiA GENETICS SA (Switzerland)
• Lunit Inc. (South Korea)
• PathAI, Inc. (US)
• QIAGEN N.V. (Netherlands)
• ConcertAI (US)
• Genomenon, Inc. (US)
• DNAnexus, Inc. (US)
• GE HealthCare Technologies Inc. (US)
• Velsera, Inc. (US)

Recent Market Developments

• In August 2025, Tempus AI completed its acquisition of Paige.AI on 22 August 2025, bringing AI digital pathology products and a large library of annotated pathology slides into its precision oncology platform. The transaction widens Tempus' multimodal dataset and adds generative AI expertise for pathology-based biomarker and drug development work.
• In January 2026, Illumina introduced the Billion Cell Atlas, a genome-wide CRISPR perturbation dataset designed to train AI models for target discovery and validation. AstraZeneca, Merck, and Eli Lilly joined as founding participants, and the atlas is the first output of Illumina's new BioInsight business, which supplies datasets and algorithms to drug developers.
• In April 2026, SOPHiA GENETICS announced that Mount Sinai Health System will adopt its AI-powered SOPHiA DDM Platform for cancer research and genomic testing, using the blood cancer and solid tumor applications. Mount Sinai joins a network of more than 990 institutions that use the platform, expanding the company's footprint among large US academic health systems.
• In July 2026, Owkin and Gustave Roussy announced a partnership to test Owkin's K Pro AI scientist inside the hospital's real-world clinical and research workflows, including large multimodal tumor profiling programs. Both organizations plan to publish the results, which should show whether agentic AI adds insight beyond established bioinformatics pipelines in oncology.

Frequently Asked Questions